Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Lancet Oncol. 2019 Mar 14;20(4):570–580. doi: 10.1016/S1470-2045(18)30905-7

Table 3.

Treatment-related toxicities that are grade 3+ or occurring in ≥10% of patients (n=32).

Toxicity Maximum Grade
1 – 2 3 4
Nausea 23 (71.9%) 3 (9.4%) -
Hyperglycemia 17 (53.1%) 3 (9.4%) 2 (6.3%)
Fatigue 18 (56.3%) 2 (6.3%) -
Diarrhea 16 (50%) - -
Vomiting 14 (43.8%) 2 (6.3%) -
Anorexia 10 (31.3%) - -
Headache 8 (25%) - -
Anemia 7 (21.9%) - -
Constipation 5 (15.6%) - -
Creatinine increased 5 (15.6%) - -
Platelet count decreased 5 (15.6%) - -
Rash acneiform 4 (12.5%) 1 (3.1%) -
Rash maculo-papular 4 (12.5%) 1 (3.1%) -
Serum amylase increased 4 (12.5%) 1 (3.1%) -
Abdominal pain 4 (12.5%) - -
Alanine aminotransferase increased 1 (3.1%) 3 (9.4%) -
Dry skin 4 (12.5%) - -
Dysgeusia 4 (12.5%) - -
Dyspnea 4 (12.5%) - -
Lipase increased 2 (6.3%) 2 (6.3%) -
Mucositis oral 4 (12.5%) - -
Investigations - Other, specify 2 (6.3%) - 1 (3.1%)
Aspartate aminotransferase increased 1 (3.1%) 1 (3.1%) -
Febrile neutropenia - - 1 (3.1%)
GGT increased - 1 (3.1%) -
Pain - 1 (3.1%) -
Rectal pain - 1 (3.1%) -
Renal Insufficiency - - 1 (3.1%)